Secarna Pharmaceuticals GmbH & Co. KG: Secarna Pharmaceutica

Compelling in vivo and in vitro data published in peer-reviewed Journal for ImmunoTherapy of Cancer (JITC)Secarna's LNAplus-based ASOs effectively stimulate TLR9 signaling, an important innate immune pathway

Related Keywords

Munich , Bayern , Germany , Geneva , Genè , Switzerland , Zeiten , Mecklenburg Vorpommern , Alexander Gebauer , Stefan Klotter , Alfred Zippelius , Frank Jaschinski , Planegg Martinsried , Mikael Pittet , Anne Hennecke Lydia Robinson Garcia , Department Of Pathology , Secarna Pharmaceuticals , Mc Services , Department Of Biomedicine , University Of Geneva , Basel University , Secarna Pharmaceuticals Gmbh Co , Secarna Pharmaceuticals Gmbh , Chief Scientific Officer , Stabile Ertr , Chart Profi Stefan Klotter , Blue Chips , Secarna , Pharmaceuticals , Mbh , Nnounces , Publication , Reclinical , Data , Showing , Durable , Antitumor , Activity , Naplus , Ased , Sos , Moth , Stimulate , Yinnate , Immune , System , Suppress , Expression ,